Sintx Technologies announces strategic vision focused on expansion

SINTX Technologies (SINT) announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company’s successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. The company said, “SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial, cranio-maxillofacial, and oncologic reconstruction… SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company’s near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards.”